| Profiles RNS

Profile

MD, University of Texas Southwestern Medical Center
MS, Yale University
MA, Yale University
BS, Houston Baptist University

Websites

	LinkedIn
	ORCID
	PubMed \| My Bibliography
	CIRA \| Yale

ORCID : 0000-0003-4184-8748

Publications
Social/Media

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis Copy PMIDs To Clipboard

Mandyam VC, Bruce RD. Chronic Pain and Opioid Use in Older People With HIV. Top Antivir Med. 2022 Dec-Jan; 29(5):419-422.View Related Profiles.

Bruce, Robert
Mandyam, Vasudev

PMID: 35191657; PMCID: PMC8862752

Bonner R, Stewart J, Upadhyay A, Bruce RD, Taylor JL. A Primary Care Intervention to Increase HIV Pre-Exposure Prophylaxis (PrEP) Uptake in Patients with Syphilis. J Int Assoc Provid AIDS Care. 2022 Jan-Dec; 21:23259582211073393.View Related Profiles.

Upadhyay, Ashish
Taylor, Jessica
Bruce, Robert
Bonner, Ryan

PMID: 35001723; PMCID: PMC8753072; DOI: 10.1177/23259582211073393;

Minja LT, Hella J, Mbwambo J, Nyandindi C, Omary US, Levira F, Mpagama S, Shimwela M, Okuma J, Gagneux S, Bruce RD, Reither K. High burden of tuberculosis infection and disease among people receiving medication-assisted treatment for substance use disorder in Tanzania. PLoS One. 2021; 16(4):e0250038. PMID: 33914753; PMCID: PMC8084249; DOI: 10.1371/journal.pone.0250038;

Kurth AE, Cherutich P, Conover R, Chhun N, Bruce RD, Lambdin BH. The Opioid Epidemic in Africa And Its Impact. Curr Addict Rep. 2018 Dec; 5(4):428-453. PMID: 32494564; PMCID: PMC7269163; DOI: 10.1007/s40429-018-0232-9;

Bruce RD. Opioid addiction, opioid addiction treatment, and HIV infection. Top Antivir Med. 2018 Sep; 26(3):89-92. PMID: 30384332; PMCID: PMC6291298

Bruce RD, Merlin J, Lum PJ, Ahmed E, Alexander C, Corbett AH, Foley K, Leonard K, Treisman GJ, Selwyn P. 2017 HIVMA of IDSA Clinical Practice Guideline for the Management of Chronic Pain in Patients Living With HIV. Clin Infect Dis. 2017 Oct 30; 65(10):e1-e37. PMID: 29020263; PMCID: PMC5848240; DOI: 10.1093/cid/cix636;

Bruce RD, Merlin J, Lum PJ, Ahmed E, Alexander C, Corbett AH, Foley K, Leonard K, Treisman GJ, Selwyn P. 2017 HIV Medicine Association of Infectious Diseases Society of America Clinical Practice Guideline for the Management of Chronic Pain in Patients Living With Human Immunodeficiency Virus. Clin Infect Dis. 2017 Oct 30; 65(10):1601-1606. PMID: 29091230; PMCID: PMC5850004; DOI: 10.1093/cid/cix848;

Harris DA, Mainardi A, Iyamu O, Rosenthal MS, Bruce RD, Pisani MA, Redlich CA. Improving the asthma disparity gap with legal advocacy? A qualitative study of patient-identified challenges to improve social and environmental factors that contribute to poorly controlled asthma. J Asthma. 2018 08; 55(8):924-932. PMID: 28872933; DOI: 10.1080/02770903.2017.1373393;

Gibson BA, Morano JP, Walton MR, Marcus R, Zelenev A, Bruce RD, Altice FL. Innovative Program Delivery and Determinants of Frequent Visitation to a Mobile Medical Clinic in an Urban Setting. J Health Care Poor Underserved. 2017; 28(2):643-662. PMID: 28529215; DOI: 10.1353/hpu.2017.0065;

Beckman AL, Bilinski A, Boyko R, Camp GM, Wall AT, Lim JK, Wang EA, Bruce RD, Gonsalves GS. New Hepatitis C Drugs Are Very Costly And Unavailable To Many State Prisoners. Health Aff (Millwood). 2016 10 01; 35(10):1893-1901. PMID: 27702964

Showing 10 of 91 results. Show More

Kayingo G, Bruce RD. HIV testing at a community health center before and after implementing universal screening. JAAPA. 2016 Aug; 29(8):45-6. PMID: 27467298; DOI: 10.1097/01.JAA.0000488696.73423.02;

Ogbuagu O, Friedland G, Bruce RD. Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. Expert Opin Drug Metab Toxicol. 2016 Jul; 12(7):721-31. PMID: 27140427; DOI: 10.1080/17425255.2016.1183644;

Ubuguyu O, Tran OC, Bruce RD, Masao F, Nyandindi C, Sabuni N, McCurdy S, Mbwambo J, Lambdin BH. Improvements in health-related quality of life among methadone maintenance clients in Dar es Salaam, Tanzania. Int J Drug Policy. 2016 Apr; 30:74-81. PMID: 27017376; PMCID: PMC4829437; DOI: 10.1016/j.drugpo.2016.03.005;

Tan AX, Kapiga S, Khoshnood K, Bruce RD. Epidemiology of Drug Use and HIV-Related Risk Behaviors among People Who Inject Drugs in Mwanza, Tanzania. PLoS One. 2015; 10(12):e0145578. PMID: 26701616; PMCID: PMC4689416; DOI: 10.1371/journal.pone.0145578;

Saleem HT, Mushi D, Hassan S, Bruce RD, Cooke A, Mbwambo J, Lambdin BH. "Can't you initiate me here?": Challenges to timely initiation on antiretroviral therapy among methadone clients in Dar es Salaam, Tanzania. Int J Drug Policy. 2016 Apr; 30:59-65. PMID: 26831364; PMCID: PMC4829458; DOI: 10.1016/j.drugpo.2015.12.009;

Durham DP, Skrip LA, Bruce RD, Vilarinho S, Elbasha EH, Galvani AP, Townsend JP. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States. Clin Infect Dis. 2016 Feb 01; 62(3):298-304. PMID: 26628566; PMCID: PMC4706637; DOI: 10.1093/cid/civ894;

Lambdin BH, Mbwambo JK, Josiah RM, Bruce RD. Service integration: opportunities to expand access to antiretroviral therapy for people who inject drugs in Tanzania. J Int AIDS Soc. 2015; 18:19936. PMID: 26202669; PMCID: PMC4511823; DOI: 10.7448/IAS.18.1.19936;

Garimella T, Wang R, Luo WL, Wastall P, Kandoussi H, DeMicco M, Bruce RD, Hwang C, Bertz R, Bifano M. Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone. Antimicrob Agents Chemother. 2015 Sep; 59(9):5503-10. PMID: 26124175; PMCID: PMC4538464; DOI: 10.1128/AAC.00478-15;

Tran OC, Bruce RD, Masao F, Ubuguyu O, Sabuni N, Mbwambo J, Lambdin BH. Implementation and Operational Research: Linkage to Care Among Methadone Clients Living With HIV in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr. 2015 Jun 01; 69(2):e43-8. PMID: 26009835; PMCID: PMC4435505; DOI: 10.1097/QAI.0000000000000582;

Hulskotte EG, Bruce RD, Feng HP, Webster LR, Xuan F, Lin WH, O'Mara E, Wagner JA, Butterton JR. Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy. Eur J Clin Pharmacol. 2015 Mar; 71(3):303-11. PMID: 25666027; DOI: 10.1007/s00228-014-1789-4;

Ogbuagu O, Bruce RD. Reaching the unreached: treatment as prevention as a workable strategy to mitigate HIV and its consequences in high-risk groups. Curr HIV/AIDS Rep. 2014 Dec; 11(4):505-12. PMID: 25342571; DOI: 10.1007/s11904-014-0238-4;

Gupta A, Mbwambo J, Mteza I, Shenoi S, Lambdin B, Nyandindi C, Doula BI, Mfaume S, Bruce RD. Active case finding for tuberculosis among people who inject drugs on methadone treatment in Dar es Salaam, Tanzania. Int J Tuberc Lung Dis. 2014 Jul; 18(7):793-8. PMID: 24902554; PMCID: PMC4506927; DOI: 10.5588/ijtld.13.0208;

Woody GE, Bruce D, Korthuis PT, Chhatre S, Poole S, Hillhouse M, Jacobs P, Sorensen J, Saxon AJ, Metzger D, Ling W. HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. J Acquir Immune Defic Syndr. 2014 Jul 01; 66(3):288-93. PMID: 24751432; PMCID: PMC4146664; DOI: 10.1097/QAI.0000000000000165;

Morano JP, Zelenev A, Walton MR, Bruce RD, Altice FL. Latent tuberculosis infection screening in foreign-born populations: a successful mobile clinic outreach model. Am J Public Health. 2014 Aug; 104(8):1508-15. PMID: 24922157; PMCID: PMC4103248; DOI: 10.2105/AJPH.2014.301897;

Lambdin BH, Masao F, Chang O, Kaduri P, Mbwambo J, Magimba A, Sabuni N, Bruce RD. Methadone treatment for HIV prevention-feasibility, retention, and predictors of attrition in Dar es Salaam, Tanzania: a retrospective cohort study. Clin Infect Dis. 2014 Sep 01; 59(5):735-42. PMID: 24855149; PMCID: PMC4809981; DOI: 10.1093/cid/ciu382;

Bruce RD, Beletsky L, Stancliff S, Bowman S. The reply. Am J Med. 2013 Nov; 126(11):e21-2. PMID: 24157295

Bruce RD, Beletsky L, Stancliff S. The reply. Am J Med. 2013 Nov; 126(11):e17. PMID: 24157293

Bruce RD. The marketing of methadone: how an effective medication became unpopular. Int J Drug Policy. 2013 Nov; 24(6):e89-90. PMID: 24246504; DOI: 10.1016/j.drugpo.2013.10.006;

Clarke TK, Crist RC, Ang A, Ambrose-Lanci LM, Lohoff FW, Saxon AJ, Ling W, Hillhouse MP, Bruce RD, Woody G, Berrettini WH. Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females. Pharmacogenomics J. 2014 Jun; 14(3):303-8. PMID: 24126707; PMCID: PMC3988270; DOI: 10.1038/tpj.2013.30;

Morano JP, Walton MR, Zelenev A, Bruce RD, Altice FL. Latent tuberculosis infection: screening and treatment in an urban setting. J Community Health. 2013 Oct; 38(5):941-50. PMID: 23728822; PMCID: PMC3781590; DOI: 10.1007/s10900-013-9704-y;

Bruce RD, Winkle P, Custodio JM, Wei X, Rhee MS, Kearney BP, Ramanathan S, Friedland GH. Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance. Antimicrob Agents Chemother. 2013 Dec; 57(12):6154-7. PMID: 24080665; PMCID: PMC3837895; DOI: 10.1128/AAC.01229-13;

Bruce RD, Lambdin B, Chang O, Masao F, Mbwambo J, Mteza I, Nyandindi C, Zamudio-Haas S, Buma D, Dunbar MS, Kilonzo G. Lessons from Tanzania on the integration of HIV and tuberculosis treatments into methadone assisted treatment. Int J Drug Policy. 2014 Jan; 25(1):22-5. PMID: 24210295; DOI: 10.1016/j.drugpo.2013.09.005;

Bruce RD. Is it time for treatment as prevention among people who inject drugs? J Acquir Immune Defic Syndr. 2013 Aug 15; 63(5):545-7. PMID: 23774878; DOI: 10.1097/QAI.0b013e31829f215e;

Bruce RD, Winkle P, Custodio JM, Wei LX, Rhee MS, Kearney BP, Ramanathan S, Friedland GH. The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. J Acquir Immune Defic Syndr. 2013 Aug 01; 63(4):480-4. PMID: 23599011; DOI: 10.1097/QAI.0b013e3182961d31;

Seewald R, Bruce RD, Elam R, Tio R, Lorenz S, Friedmann P, Rabin D, Garger YB, Bonilla V, Perlman DC. Effectiveness and feasibility study of routine HIV rapid testing in an urban methadone maintenance treatment program. Am J Drug Alcohol Abuse. 2013 Jul; 39(4):247-51. PMID: 23841865; PMCID: PMC4196874; DOI: 10.3109/00952990.2013.798662;

Lambdin BH, Bruce RD, Chang O, Nyandindi C, Sabuni N, Zamudio-Haas S, McCurdy S, Masao F, Ivo Y, Msami A, Ubuguy O, Mbwambo J. Identifying programmatic gaps: inequities in harm reduction service utilization among male and female drug users in Dar es Salaam, Tanzania. PLoS One. 2013; 8(6):e67062. PMID: 23825620; PMCID: PMC3692420; DOI: 10.1371/journal.pone.0067062;

Bowman S, Eiserman J, Beletsky L, Stancliff S, Bruce RD. Reducing the health consequences of opioid addiction in primary care. Am J Med. 2013 Jul; 126(7):565-71. PMID: 23664112; DOI: 10.1016/j.amjmed.2012.11.031;

Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Rev Clin Pharmacol. 2013 May; 6(3):249-69. PMID: 23656339; PMCID: PMC4198941; DOI: 10.1586/ecp.13.18;

Crist RC, Clarke TK, Ang A, Ambrose-Lanci LM, Lohoff FW, Saxon AJ, Ling W, Hillhouse MP, Bruce RD, Woody G, Berrettini WH. An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. Neuropsychopharmacology. 2013 Sep; 38(10):2003-10. PMID: 23612435; PMCID: PMC3746708; DOI: 10.1038/npp.2013.99;

Kresina TF, Bruce RD, Mulvey KP. Evidence-based prevention interventions for people who use illicit drugs. Adv Prev Med. 2013; 2013:360957. PMID: 23573423; PMCID: PMC3610384; DOI: 10.1155/2013/360957;

Douglas Bruce R, Moody DE, Chodkowski D, Andrews L, Fang WB, Morrison J, Parsons TL, Friedland GH. Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. Am J Drug Alcohol Abuse. 2013 Mar; 39(2):80-5. PMID: 23421567; DOI: 10.3109/00952990.2013.764885;

Qian F, Bolen CR, Jing C, Wang X, Zheng W, Zhao H, Fikrig E, Bruce RD, Kleinstein SH, Montgomery RR. Impaired toll-like receptor 3-mediated immune responses from macrophages of patients chronically infected with hepatitis C virus. Clin Vaccine Immunol. 2013 Feb; 20(2):146-55. PMID: 23220997; PMCID: PMC3571267; DOI: 10.1128/CVI.00530-12;

Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, Ang A, Doraimani G, Tasissa G, Lokhnygina Y, Leimberger J, Bruce RD, McCarthy J, Wiest K, McLaughlin P, Bilangi R, Cohen A, Woody G, Jacobs P. Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend. 2013 Feb 01; 128(1-2):71-6. PMID: 22921476; PMCID: PMC3543467; DOI: 10.1016/j.drugalcdep.2012.08.002;

Vourvahis M, Wang R, Gruener DM, Bruce RD, Haider S, Tawadrous M. Effect of lersivirine co-administration on pharmacokinetics of methadone in healthy volunteers. Drug Alcohol Depend. 2012 Nov 01; 126(1-2):183-8. PMID: 22682979; DOI: 10.1016/j.drugalcdep.2012.05.009;

Schwarz R, Zelenev A, Bruce RD, Altice FL. Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence. J Subst Abuse Treat. 2012 Dec; 43(4):451-7. PMID: 22534003; PMCID: PMC3419304; DOI: 10.1016/j.jsat.2012.03.008;

Bruce RD, Eiserman J, Acosta A, Gote C, Lim JK, Altice FL. Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication. Am J Drug Alcohol Abuse. 2012 May; 38(3):206-12. PMID: 22242700; PMCID: PMC5573865; DOI: 10.3109/00952990.2011.643975;

Bruce RD. Additional explanation for lack of pharmacodynamic interaction between atazanavir and buprenorphine reported by Vergara-Rodriquez et al. J Acquir Immune Defic Syndr. 2011 Dec 01; 58(4):e112; author reply e112-3. PMID: 22033233; DOI: 10.1097/QAI.0b013e31822c1d28;

Bruce RD. One stop shopping - bringing services to drug users. Int J Drug Policy. 2012 Mar; 23(2):104. PMID: 22093675; DOI: 10.1016/j.drugpo.2011.09.008;

Wolfe D, Carrieri MP, Dasgupta N, Wodak A, Newman R, Bruce RD. Concerns about injectable naltrexone for opioid dependence. Lancet. 2011 Apr 30; 377(9776):1468-70. PMID: 21529930; DOI: 10.1016/S0140-6736(10)62056-9;

Bruce RD, Moody DE, Fang WB, Chodkowski D, Andrews L, Friedland GH. Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone. Am J Drug Alcohol Abuse. 2011 Jul; 37(4):224-8. PMID: 21438849; DOI: 10.3109/00952990.2011.568081;

Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, Cunningham CO, Sullivan LE, Vergara-Rodriguez P, Fiellin DA, Cajina A, Botsko M, Nandi V, Gourevitch MN, Finkelstein R. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011 Mar 01; 56 Suppl 1:S22-32. PMID: 21317590; PMCID: PMC3263431; DOI: 10.1097/QAI.0b013e318209751e;

Copenhaver MM, Lee IC, Margolin A, Bruce RD, Altice FL. Testing an optimized community-based human immunodeficiency virus (HIV) risk reduction and antiretroviral adherence intervention for HIV-infected injection drug users. Subst Abus. 2011 Jan; 32(1):16-26. PMID: 21302180; PMCID: PMC3071583; DOI: 10.1080/08897077.2011.540466;

Saber-Tehrani AS, Bruce RD, Altice FL. Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence. Am J Drug Alcohol Abuse. 2011 Jan; 37(1):1-11. PMID: 21247284; DOI: 10.3109/00952990.2010.540279;

Bruce RD, Altice FL, Moody DE, Morse GD, Andrews L, Lin SN, Fang WB, Ma Q, Friedland GH. Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2010 Aug; 54(5):511-4. PMID: 20672450; PMCID: PMC4841260; DOI: 10.1097/qai.0b013e3181d3cad3;

Bruce RD. Methadone as HIV prevention: high volume methadone sites to decrease HIV incidence rates in resource limited settings. Int J Drug Policy. 2010 Mar; 21(2):122-4. PMID: 19931444; PMCID: PMC2839048; DOI: 10.1016/j.drugpo.2009.10.004;

Bruce RD. Medical interventions for addictions in the primary care setting. Top HIV Med. 2010 Feb-Mar; 18(1):8-12. PMID: 20305310

Bruce RD, Kresina TF, McCance-Katz EF. Medication-assisted treatment and HIV/AIDS: aspects in treating HIV-infected drug users. AIDS. 2010 Jan 28; 24(3):331-40. PMID: 19910788; DOI: 10.1097/QAD.0b013e32833407d3;

Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, Friedland GH. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug Alcohol Depend. 2009 Dec 01; 105(3):234-9. PMID: 19726139; PMCID: PMC2779257; DOI: 10.1016/j.drugalcdep.2009.07.007;

Kresina TF, Bruce RD, McCance-Katz EF. Medication assisted treatment in the treatment of drug abuse and dependence in HIV/AIDS infected drug users. Curr HIV Res. 2009 Jul; 7(4):354-64. PMID: 19601770; DOI: 10.2174/157016209788680598;

Dubrow R, Sikkema KJ, Mayer KH, Bruce RD, Julian P, Rodriguez I, Beckwith C, Roome A, Dunne D, Boeving A, Kidder TJ, Jenkins H, Dobson M, Becker J, Merson MH. Diagnosis of acute HIV infection in Connecticut. Conn Med. 2009 Jun-Jul; 73(6):325-31. PMID: 19637661; PMCID: PMC3072267

Maru DS, Bruce RD, Walton M, Springer SA, Altice FL. Persistence of virological benefits following directly administered antiretroviral therapy among drug users: results from a randomized controlled trial. J Acquir Immune Defic Syndr. 2009 Feb 01; 50(2):176-81. PMID: 19131891; PMCID: PMC2670996; DOI: 10.1097/QAI.0b013e3181938e7e;

Bruce RD, Govindasamy S, Sylla L, Kamarulzaman A, Altice FL. Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market. Am J Drug Alcohol Abuse. 2009; 35(2):68-72. PMID: 19212931; PMCID: PMC2791788; DOI: 10.1080/00952990802585406;

Schwarz RK, Bruce RD, Ball SA, Herme M, Altice FL. Comparison of tuberculin skin testing reactivity in opioid-dependent patients seeking treatment with methadone versus buprenorphine: policy implications for tuberculosis screening. Am J Drug Alcohol Abuse. 2009; 35(6):439-44. PMID: 20014914; DOI: 10.3109/00952990903447741;

Kresina TF, Bruce RD, Lubran R, Clark HW. Integration of viral hepatitis services into opioid treatment programs. J Opioid Manag. 2008 Nov-Dec; 4(6):369-81. PMID: 19192765; DOI: 10.5055/jom.2008.0041;

Maru DS, Bruce RD, Basu S, Altice FL. Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations. Clin Infect Dis. 2008 Oct 01; 47(7):952-61. PMID: 18715156; PMCID: PMC4847716; DOI: 10.1086/591707;

Springer SA, Bruce RD. A pilot survey of attitudes and knowledge about opioid substitution therapy for HIV-infected prisoners. J Opioid Manag. 2008 Mar-Apr; 4(2):81-6. PMID: 18557164; PMCID: PMC2476214; DOI: 10.5055/jom.2008.0012;

Bruce RD, Schleifer RA. Ethical and human rights imperatives to ensure medication-assisted treatment for opioid dependence in prisons and pre-trial detention. Int J Drug Policy. 2008 Feb; 19(1):17-23. PMID: 18226517; PMCID: PMC2366202; DOI: 10.1016/j.drugpo.2007.11.019;

Bruce RD, Altice FL, Friedland GH. Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice. Expert Rev Clin Pharmacol. 2008 Jan; 1(1):115-27. PMID: 24410515; DOI: 10.1586/17512433.1.1.115;

Bruce RD, Govindasamy S, Sylla L, Haddad MS, Kamarulzaman A, Altice FL. Case series of buprenorphine injectors in Kuala Lumpur, Malaysia. Am J Drug Alcohol Abuse. 2008; 34(4):511-7. PMID: 18584580; DOI: 10.1080/00952990802122259;

Maru DS, Bruce RD, Walton M, Mezger JA, Springer SA, Shield D, Altice FL. Initiation, adherence, and retention in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Behav. 2008 Mar; 12(2):284-93. PMID: 18085432; PMCID: PMC2693908; DOI: 10.1007/s10461-007-9336-2;

Maru DS, Kozal MJ, Bruce RD, Springer SA, Altice FL. Directly administered antiretroviral therapy for HIV-infected drug users does not have an impact on antiretroviral resistance: results from a randomized controlled trial. J Acquir Immune Defic Syndr. 2007 Dec 15; 46(5):555-63. PMID: 18193497; PMCID: PMC2684061; DOI: 10.1097/qai.0b013e318158c0bd;

Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin Infect Dis. 2007 Sep 15; 45(6):770-8. PMID: 17712763; PMCID: PMC2693907; DOI: 10.1086/521166;

Bruce RD. Editorial comment: primary care and psychosocial issues in pain. AIDS Read. 2007 Jun; 17(6):313. PMID: 17632938

Sylla L, Bruce RD, Kamarulzaman A, Altice FL. Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services. Int J Drug Policy. 2007 Aug; 18(4):306-12. PMID: 17689379; PMCID: PMC2696234; DOI: 10.1016/j.drugpo.2007.03.001;

Bruce RD, Altice FL. Clinical care of the HIV-infected drug user. Infect Dis Clin North Am. 2007 Mar; 21(1):149-79, ix. PMID: 17502234; PMCID: PMC2128697; DOI: 10.1016/j.idc.2007.03.009;

Bruce RD, Dvoryak S, Sylla L, Altice FL. HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implications. Int J Drug Policy. 2007 Aug; 18(4):326-8. PMID: 17689382; PMCID: PMC2084072; DOI: 10.1016/j.drugpo.2006.12.011;

Basu S, Bruce RD, Barry DT, Altice FL. Pharmacological pain control for human immunodeficiency virus-infected adults with a history of drug dependence. J Subst Abuse Treat. 2007 Jun; 32(4):399-409. PMID: 17481463; PMCID: PMC2128698; DOI: 10.1016/j.jsat.2006.10.005;

Bruce RD, Altice FL. Case series on the safe use of buprenorphine/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases. Am J Drug Alcohol Abuse. 2007; 33(6):869-74. PMID: 17994482; DOI: 10.1080/00952990701653875;

Copenhaver MM, Bruce RD, Altice FL. Behavioral counseling content for optimizing the use of buprenorphine for treatment of opioid dependence in community-based settings: a review of the empirical evidence. Am J Drug Alcohol Abuse. 2007; 33(5):643-54. PMID: 17891657; PMCID: PMC2274830; DOI: 10.1080/00952990701522674;

Bruce RD, McCance-Katz E, Kharasch ED, Moody DE, Morse GD. Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clin Infect Dis. 2006 Dec 15; 43 Suppl 4:S216-23. PMID: 17109308

Sullivan LE, Bruce RD, Haltiwanger D, Lucas GM, Eldred L, Finkelstein R, Fiellin DA. Initial strategies for integrating buprenorphine into HIV care settings in the United States. Clin Infect Dis. 2006 Dec 15; 43 Suppl 4:S191-6. PMID: 17109306; DOI: 10.1086/508183;

Smith-Rohrberg D, Mezger J, Walton M, Bruce RD, Altice FL. Impact of enhanced services on virologic outcomes in a directly administered antiretroviral therapy trial for HIV-infected drug users. . 2006 Dec 01; 43 Suppl 1:S48-53. PMID: 17133204

Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr. 2006 Apr 15; 41(5):563-72. PMID: 16652030; DOI: 10.1097/01.qai.0000219769.89679.ec;

Bruce RD, Altice FL. Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir. AIDS. 2006 Mar 21; 20(5):783-4. PMID: 16514314; DOI: 10.1097/01.aids.0000216384.22432.9a;

Basu S, Smith-Rohrberg D, Bruce RD, Altice FL. Models for integrating buprenorphine therapy into the primary HIV care setting. Clin Infect Dis. 2006 Mar 01; 42(5):716-21. PMID: 16447120; DOI: 10.1086/500200;

Basu S, Chwastiak LA, Bruce RD. Clinical management of depression and anxiety in HIV-infected adults. AIDS. 2005 Dec 02; 19(18):2057-67. PMID: 16284454; DOI: 10.1097/01.aids.0000182518.84407.32;

Kresina TF, Eldred L, Bruce RD, Francis H. Integration of pharmacotherapy for opioid addiction into HIV primary care for HIV/hepatitis C virus-co-infected patients. AIDS. 2005 Oct; 19 Suppl 3:S221-6. PMID: 16251822; DOI: 10.1097/01.aids.0000192093.46506.e5;

Kresina TF, Bruce RD, Cargill VA, Cheever LW. Integrating care for hepatitis C virus (HCV) and primary care for HIV for injection drug users coinfected with HIV and HCV. Clin Infect Dis. 2005 Jul 01; 41 Suppl 1:S83-8. PMID: 16265621; DOI: 10.1086/429502;

Altice FL, Bruce RD, Walton MR, Buitrago MI. Adherence to hepatitis B virus vaccination at syringe exchange sites. J Urban Health. 2005 Mar; 82(1):151-61. PMID: 15746385; PMCID: PMC3456633; DOI: 10.1093/jurban/jti016;

Altice FL, Mezger JA, Hodges J, Bruce RD, Marinovich A, Walton M, Springer SA, Friedland GH. Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replication. Clin Infect Dis. 2004 Jun 01; 38 Suppl 5:S376-87. PMID: 15156426; DOI: 10.1086/421400;

Bruce RD, Altice FL. Editorial comment: why treat three conditions when it is one patient? AIDS Read. 2003 Aug; 13(8):378-9. PMID: 14524323

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Tweets by rdouglasbrucemd?lang=en

Twitter likes by rdouglasbrucemd?lang=en

Chronic Pain and Opioid Use in Older People with HIV

Contact for Mentoring: